FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200601507> ?p ?o ?g. }

• W4200601507 endingPage "17" @default.
• W4200601507 startingPage "1" @default.
• W4200601507 abstract "Cellular miRNAs are expressed in tissue fluids with sufficient amounts and were identified as potential molecular targets for studying the physiological mechanisms and correlations with many human diseases particularly diabetes. However, molecular-based changes among older adults with diabetes mellitus (DM) are rarely fully elucidated.This study is aimed at identifying circulating miRNAs, which hold the potential to serve as biomarkers for the immune-inflammatory changes in older T2D patients with moderate and poor glycemic control status. In addition, the association of both myokines and osteopontin (OPN) levels with circulating miRNAs was identified.A total of 80 subjects aged 20-80 years were invited during the period of October 2017-May 2018 to participate in this descriptive cross-sectional study. All subjects were diagnosed with T2D for more than 5 years. Subjects were grouped based on glycemic control (HbA1c values) into two groups: moderate glycemic control (>7-8% HbA1c, no = 30) and poor glycemic control (>8% HbA1c, no = 50), respectively. Diabetic control parameters, fasting blood sugar (FS), HbA1c, fasting insulin (IF), insulin resistance (IR), HOMA-IR, inflammatory cytokines (IL-6, IL-8, IL-18, IL-23, TNF-α, and CRP), osteopontin, and myokines (adropin and irisin) were estimated by colorimetric and immune ELISA assays, respectively. In addition, real-time RT-PCR analysis was performed to evaluate the expression of circulating miRNAs, miR-146a and miR-144, in the serum of all diabetic subjects.In this study, T2D patients with poor glycemic control showed a significant increase in the serum levels of IL-6, IL-8, IL-18, IL-23, TNF-α, CRP, and OPN and a reduction in the levels of myokines, adropin and irisin, compared to patients with moderate glycemic control. The results obtained are significantly correlated with the severity of diabetes measured by HbA1c, FS, IF, and HOMA-IR. In addition, baseline expression of miR-146a is significantly reduced and miR-144 is significantly increased in T2D patients with poor glycemic control compared to those with moderate glycemic control. In all diabetic groups, the expression of miR-146a and miR-144 is significantly correlated with diabetic controls, inflammatory cytokines, myokines, and serum levels of OPN. Respective of gender, women with T2D showed more significant change in the expressed miRNAs, inflammatory cytokines, OPN, and serum myokine markers compared to men. ROC analysis identified AUC cutoff values of miR-146a, miR-144, adropin, irisin, and OPN expression levels with considerable specificity and sensitivity which recommends the potential use of adropin, irisin, and OPN as diagnostic biomarkers for diabetes with varying glycemic control status.In this study, molecular expression of certain microRNA species, such as miR-146a and miR-144, was identified and significantly associated with parameters of disease severity, HbA1c, inflammatory cytokines, myokines, and serum osteopontin in T2D patients with moderate and poor glycemic control. The AUC cutoff values of circulating miRNAs, miR-146a and miR-144; myokines, adropin and irisin; and serum OPN were significantly identified by ROC analysis which additionally recommends the potential use of these biomarkers, miR-146a, miR-144, adropin, irisin, and OPN, as diagnostic biomarkers with considerable specificity and sensitivity for diabetes in patients with varying glycemic control status." @default.
• W4200601507 created "2021-12-31" @default.
• W4200601507 creator A5000968970 @default.
• W4200601507 creator A5034779517 @default.
• W4200601507 creator A5053370248 @default.
• W4200601507 date "2021-12-07" @default.
• W4200601507 modified "2023-10-15" @default.
• W4200601507 title "Expression of Circulating MicroRNAs and Myokines and Interactions with Serum Osteopontin in Type 2 Diabetic Patients with Moderate and Poor Glycemic Control: A Biochemical and Molecular Study" @default.
• W4200601507 cites W130907858 @default.
• W4200601507 cites W1524952873 @default.
• W4200601507 cites W1531237901 @default.
• W4200601507 cites W1923599839 @default.
• W4200601507 cites W1924227910 @default.
• W4200601507 cites W1964055985 @default.
• W4200601507 cites W1965613155 @default.
• W4200601507 cites W1966706607 @default.
• W4200601507 cites W1970643565 @default.
• W4200601507 cites W1971441087 @default.
• W4200601507 cites W1976124390 @default.
• W4200601507 cites W1978393167 @default.
• W4200601507 cites W1979380754 @default.
• W4200601507 cites W1981034583 @default.
• W4200601507 cites W1981377841 @default.
• W4200601507 cites W1986876174 @default.
• W4200601507 cites W1988012375 @default.
• W4200601507 cites W1989635266 @default.
• W4200601507 cites W1989840237 @default.
• W4200601507 cites W1997443963 @default.
• W4200601507 cites W1998802885 @default.
• W4200601507 cites W2004035470 @default.
• W4200601507 cites W2006202614 @default.
• W4200601507 cites W2006441826 @default.
• W4200601507 cites W2006891931 @default.
• W4200601507 cites W2009818179 @default.
• W4200601507 cites W2013780938 @default.
• W4200601507 cites W2013966444 @default.
• W4200601507 cites W2016470916 @default.
• W4200601507 cites W2018135697 @default.
• W4200601507 cites W2018459966 @default.
• W4200601507 cites W2021049560 @default.
• W4200601507 cites W2022930571 @default.
• W4200601507 cites W2026181445 @default.
• W4200601507 cites W2029821021 @default.
• W4200601507 cites W2034586402 @default.
• W4200601507 cites W2034667484 @default.
• W4200601507 cites W2047709182 @default.
• W4200601507 cites W2047902687 @default.
• W4200601507 cites W2050456578 @default.
• W4200601507 cites W2051696948 @default.
• W4200601507 cites W2054893928 @default.
• W4200601507 cites W2058184727 @default.
• W4200601507 cites W2059185496 @default.
• W4200601507 cites W2059743234 @default.
• W4200601507 cites W2061998727 @default.
• W4200601507 cites W2064843795 @default.
• W4200601507 cites W2066562597 @default.
• W4200601507 cites W2067504868 @default.
• W4200601507 cites W2069046566 @default.
• W4200601507 cites W2071073097 @default.
• W4200601507 cites W2071224053 @default.
• W4200601507 cites W2072454574 @default.
• W4200601507 cites W2073587768 @default.
• W4200601507 cites W2077737366 @default.
• W4200601507 cites W2078697953 @default.
• W4200601507 cites W2080660353 @default.
• W4200601507 cites W2083889682 @default.
• W4200601507 cites W2084483597 @default.
• W4200601507 cites W2085397620 @default.
• W4200601507 cites W2090618386 @default.
• W4200601507 cites W2091503140 @default.
• W4200601507 cites W2095336321 @default.
• W4200601507 cites W2096033670 @default.
• W4200601507 cites W2096252794 @default.
• W4200601507 cites W2098444146 @default.
• W4200601507 cites W2101508556 @default.
• W4200601507 cites W2101731399 @default.
• W4200601507 cites W2101926861 @default.
• W4200601507 cites W2105686255 @default.
• W4200601507 cites W2106016477 @default.
• W4200601507 cites W2108567141 @default.
• W4200601507 cites W2111188992 @default.
• W4200601507 cites W2112758818 @default.
• W4200601507 cites W2114192910 @default.
• W4200601507 cites W2116369874 @default.
• W4200601507 cites W2116381107 @default.
• W4200601507 cites W2126185932 @default.
• W4200601507 cites W2127714110 @default.
• W4200601507 cites W2129882955 @default.
• W4200601507 cites W2130585857 @default.
• W4200601507 cites W2132080783 @default.
• W4200601507 cites W2132428623 @default.
• W4200601507 cites W2134099620 @default.
• W4200601507 cites W2136024338 @default.
• W4200601507 cites W2138283896 @default.
• W4200601507 cites W2140657430 @default.
• W4200601507 cites W2142470321 @default.
• W4200601507 cites W2144317542 @default.
• W4200601507 cites W2149494021 @default.

• next